LAVA Therapeutics Amends Share Purchase Agreement

LAVA Therapeutics ( (LVTX) ) has provided an announcement.

On October 17, 2025, LAVA Therapeutics N.V. and XOMA Royalty Corporation announced an amendment to their share purchase agreement, affecting the tender offer for LAVA’s shares. The amendment reduces the cash amount per share and introduces a contingent value right (CVR) with potential cash payments based on future proceeds from LAVA’s assets. The minimum net-cash closing condition was also lowered, and the offer’s expiration was extended to November 12, 2025. The amendment reflects current understandings of potential liabilities and expected cash balances, impacting LAVA’s shareholders and the company’s strategic positioning.

The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.

Spark’s Take on LVTX Stock

According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.

The overall stock score is primarily impacted by the company’s weak financial performance, characterized by negative profitability and cash flow challenges. Technical analysis provides some positive momentum, but the valuation remains unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.

To see Spark’s full report on LVTX stock, click here.

More about LAVA Therapeutics

LAVA Therapeutics N.V. is a biopharmaceutical company specializing in the development of clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform. The company has partnered with Johnson & Johnson and Pfizer to target hematologic cancers and solid tumors, respectively.

Average Trading Volume: 252,488

Technical Sentiment Signal: Hold

Current Market Cap: $39.98M

See more insights into LVTX stock on TipRanks’ Stock Analysis page.